Perioperative chemotherapy for gastric cancer: the current state
- 作者: Lyadov V1,2, Pardabekova O2, Lyadova M2
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Clinical Hospital №1 MEDSI
- 期: 卷 20, 编号 2 (2018)
- 页面: 56-60
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29552
- DOI: https://doi.org/10.26442/1815-1434_2018.2.56-60
- ID: 29552
如何引用文章
全文:
详细
作者简介
V Lyadov
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation; Clinical Hospital №1 MEDSI
Email: vlyadov@gmail.com
канд. мед. наук, доц. каф. онкологии, хирург отд-ния торакоабдоминальной онкологии и маммологии КБ №1 143442, Russian Federation, Moskovskaia obl., Krasnogorskii r-n, Piatnitskoe sh., 6-i km
O Pardabekova
Clinical Hospital №1 MEDSI
Email: Olesya.pardabekova@mail.ru
врач-онколог отд-ния онкологии (химиотерапии) КБ №1 143442, Russian Federation, Moskovskaia obl., Krasnogorskii r-n, Piatnitskoe sh., 6-i km
M Lyadova
Clinical Hospital №1 MEDSI
Email: m.skrypnikova@mail.ru
канд. мед. наук, зав. отд-нием онкологии (химиотерапии) КБ №1 143442, Russian Federation, Moskovskaia obl., Krasnogorskii r-n, Piatnitskoe sh., 6-i km
参考
- Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2014.
- Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А.Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2017.
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. М., 2015.]
- Smyth E.C, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (5): v38-v49.
- Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017; 18: 69.
- Cunningham D, Allum W.H, Stenning S.P et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
- Smyth E.C, Fassan M, Cunningham D et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol 2016; 34 (23): 2721-7.
- Smyth E.C, Wotherspoon A, Peckitt C et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017.
- Ychou M, Boige V, Pignon J.P et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-21.
- Alderson D, Cunningham D, Nankivell M et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol 2017; 18 (9): 1249-60.
- Ferri L.E, Ades S, Alcindor T et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol 2012; 23 (6): 1512-7.
- Thuss-Patience P.C, Hofheinz R.D, Arnold D et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the arbeitsgemeinschaft internistische onkologie (AIO){dagger}. Ann Oncol 2012; 23: 2827-34.
- Biffi R, Fazio N, Luca F et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010; 16: 868-74.
- Schulz C, Kullmann F, Kunzmann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer 2015; 137 (3): 678-85.
- Lorenzen S, Pauligk C, Homann N. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer 2013; 108 (3): 519-26.
- Al-Batran S.E, Hofheinz R.D, Pauligk C. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17 (12): 1697-708.
- Al-Batran S.E, Homann N, Schmalenberg H et al. Peri-operative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35 (Suppl. 15): 4004.
- Lorenzen S, Thuss-Patience P, Al-Batran S.E. et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol 2013; 24 (8): 2068-73.
- Al-Batran S-E, zur Hausen G, NCT02581462 - FLOT vs. FLOT/herceptin/pertuzumab for perioperative therapy of adenocarcinoma of the stomach and gastroesophageal junction expressing HER-2. A phase II/III trial of the AIO. https://clinicaltrials.gov/ ct2/show/ NCT02581462
- Bang Y.J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomized controlled trial. Lancet 2010; 376 (9742): 687-97.
- Wagner A.D. NCT02205047 - neoadjuvant study using trastuzumab or trastuzumab with pertuzumab in gastric or gastroesophageal junction adenocarcinoma (INNOVATION). https://clinical trials.gov/ct2/show/NCT02205047
- Cunningham D, Stenning S.P, Smyth E.C et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-70.
- Al-Batran S-E, Bankstahl U.S. NCT02661971 - perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma - RAMSES - a phase II/III trial of the AIO. https://clinicaltrials.gov/ct2/show/ NCT02661971
- Sun W. NCT02943603 - a study of perioperative mFOLFOX6 plus pembrolizumab in patients with potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) and stomach. https://clinicaltrials.gov/ct2/show/NCT02943603
- Otap D, Shah M, Oberstein P. NCT02918162 - perioperative chemo and pembrolizumab in gastric cancer. https://clinicaltrials.gov/ ct2/show/NCT02918162
- Fujitani K, Yang H-K, Mizusawa J et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17: 309-18.
- Al-Batran S.E, Homann N, Pauligk C et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 2017.
- Al-Batran S.E, Goetze T.O, Mueller D.W et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017; 17 (1): 893.